Work Packages

 

Neuronet was grounded on a very small, operational consortium, which underpinned the coordination and support action activities with no explicit or implicit academic bias. The overall project consisted of five so called Work Packages (teams). Every team had two designated leaders and a number of other partners who contributed to the work during the funding period (March 2019 - August 2022)

Work Package 1: Projects & Impact analysis

Takeda-Development-Centre-Europe-Limited-(TAKEDA)
Takeda Pharmaceuticals International AG
Dalia Dawoud
Dalia Dawoud National Institute for Health and Care Excellence
National Institute
for Health and Care
Excellence (NICE)

WP1 was a descriptive and methodological work package that analysed the Innovative Medicines Initiative’s (IMI) neurodegeneration diseases project portfolio to enable an integrated view of relative specialisation, timelines, expertise and outputs.

 

Show More

Objectives

  • Develop benchmarks and indicators to analyse existing IMI neurodegeneration diseases projects and related initiatives.
  • Understand existing IMI neurodegeneration diseases projects, both in terms of their relative strengths and their unmet needs, their expected outputs and timelines.
  • Assess the scientific and socio-economic impact of the IMI neurodegeneration portfolio across the EU.
  • Map international initiatives and efforts in neurodegenerative diseases, including a gap analysis.

Work Package 2: Programme Integration

Laurent Pradier

Sanofi-Aventis Recherche
& Développement (SARD)

Carlos Díaz

Synapse Research
Management Partners S.L
(SYNAPSE)

 

WP2 was a core work package that created the structure, procedures and workflows for the Neuronet ‘switchboard’ with participation of the IMI neurodegeneration diseases projects and other relevant initiatives.

 

Show More

Objectives

  • Create and implement the governance and organisational structures of Neuronet, associated workflows and procedures.
  • Support transition from a project portfolio to an integrated IMI neurodegeneration programme by promoting and enabling operational interactions, collaborations and synergies among projects and stakeholders.
  • Create a channel to and from the IMI Neurodegeneration Strategic Governance Group (SGG) on opportunities and identified gaps to explore further research initiatives.

Work Package 3: Tools and Services

Arthur Roach

Parkinson’s disease society
of the United Kingdom LGB
(Parkinson’s UK)

Carlos Díaz

Synapse Research
Management Partners S.L
(SYNAPSE)

 

WP3 developed specific tools and services provided by Neuronet to support IMI neurodegenerative diseases projects on areas where unmet needs are detected.

 

Show More

Objectives

  • Develop a web-based IMI neurodegenerative diseases Knowledge Base as a portal for the whole IMI neurodegenerative diseases programme compiling information on the projects, results, expertise and impact.
  • Develop guidance on best practice and standards with regards to data and sample sharing and use.
  • Provide technical and process guidance on interactions with regulators, Health Technology Assessment bodies, and payers (where appropriate) across the EU on specific outputs resulting from the different IMI neurodegenerative diseases projects.
  • Develop guidance in relation to patient privacy, General Data Protection Regulation (GDPR) and informed consent.
  • Provide advice and support to projects in terms of sustainability and value proposition development.

Work Package 4: Dissemination & Outreach

Jean Georges

Alzheimer Europe (AE)

 

F. Hoffmann-La Roche AG

(ROCHE)

 

WP4 fulfilled a dual role:

  1. promoting synergy across the individual dissemination and communication activities of the different IMI neurodegenerative diseases projects to maximise their visibility and impact, and optimize use of resources;
  2. fulfilling Neuronet’s ‘ambassador’ role by reaching out to relevant stakeholders and initiatives worldwide.

 

Show More

Objectives

  • Compile dissemination and communication strategies across IMI neurodegenerative diseases projects, identifying communication experts in each project, as well as synergies and opportunities for efficiency.
  • Develop a global communication strategy for the IMI neurodegeneration portfolio identifying the appropriate audiences, tools and activities.
  • Carry out the dissemination and communication activities identified in the communication strategy in collaboration with a community of communication experts from the different projects.
  • Serve as ‘ambassador’ of the IMI neurodegenerative diseases portfolio towards external initiatives and stakeholders.
  • Organise an annual networking and communication event involving all IMI neurodegeneration projects and relevant external experts and stakeholders.

Work Package 5: Coordination and Support Action Management & Sustainability

Michael Leslie Hutton

Eli Lilly and Company Ltd
(Eli Lilly)

Carlos Diaz

Synapse Research
Management Partners S.L
(SYNAPSE)

Lennert Steukers

Janssen Pharmaceutica NV (Janssen)

 

 

WP5 focused on providing coordination and professional project management capacity to resolve trade-offs between scope, time, cost and quality to ensure adequate progress and successful completion of Neuronet.

Show More

Objectives

  • Establish a project management and governance structure enabling efficient execution of the Coordination and Support Action (CSA), including decision-making, conflict resolution, reporting and accountability.
  • Manage resources, procedures and tools to deliver the CSA to plan, within time and budget, including risk management and quality control procedures on deliverables.
  • Ensure effective communication and work dynamics between consortium members to help drive the whole Consortium as a team towards successful completion.
  • Ensure appropriate administration, monitoring, reporting and legal management in support of the CSA.
  • Explore and develop sustainability models for the long-term viability of Neuronet.